Τρίτη 20 Οκτωβρίου 2020

 

Interleukin-12 message in a bottle.
Authors: Cirella A, Berraondo P, Di Trani CA, Melero I Abstract IL-12 is a very potent cancer immunotherapy agent but is difficult to harness safely if given systemically. Local gene-transfer aims to confine the effects of IL-12 to malignant tissues, thus avoiding toxicity. Lipid-nanoparticled messenger RNA achieves IL-12 expression and efficacy in mouse models, opening the way to an ongoing trial. PMID: 33004432 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Selected Articles from This Issue.
Authors: PMID: 33004470 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Next-Generation Sequencing of Cerebrospinal Fluid: How can a liquid be like a solid?
Authors: Marmarelis ME, Bauml JM Abstract The APOLLO investigators showed that NGS of cerebrospinal fluid can reveal molecular alterations - how should this affect our management approach? PMID: 32998958 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors.
CONCLUSIONS: These data show the potential of statins as pharmacologic modulators of endocytic proteins for improved tumors' accumulation of monoclonal antibodies. The translational significance of these findings lies in the potential of statins to temporarily modulate the heterogeneous presence of receptors at the cell membrane, a characteristic often associated with poor response in tumors to therapeutic antibodies. PMID: 32998959 [PubMed - as supplied by publisher] (Source: Clinical Cancer...
Clinical Cancer Research
1w
Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy.
CONCLUSIONS: Together, these data suggest that itacitinib has potential as a prophylactic agent for the prevention of CAR T-cell-induced CRS, and a phase II clinical trial of itacitinib for prevention of CRS induced by CAR T-cell therapy has been initiated (NCT04071366). PMID: 32998963 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy.
CONCLUSIONS: There is a subset of tumors, frequently classified as mesenchymal or IGS cluster 23, that may be identified with immunohistochemistry and could well be optimal candidates to immunotherapy. PMID: 32998960 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer.
CONCLUSION: Triplet therapy with endocrine therapy and mTOR and CDK4/6 inhibition provides clinical benefit and an acceptable safety profile in previously treated postmenopausal women with HR+, HER2- ABC. PMID: 32998962 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
A phase 1b study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia.
CONCLUSIONS: The onvansertib and decitabine combination was well tolerated and had anti-leukemic activity particularly in patients with target engagement and decreased mutant ctDNA following treatment. This combination will be further investigated in the ongoing phase 2 trial. PMID: 32998961 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.
CONCLUSIONS: Certain survivors are more susceptible to cisplatin-induced neurotoxicity, markedly increasing likelihood of developing numerous neuro-otological symptoms that affect quality of life. Genome-wide analysis identified genetic variation in FAM20C as a potentially important risk factor. PMID: 32998964 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Phase 1 Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
CONCLUSIONS: Alvocidib can be safely administered prior to 7+3 induction with encouraging clinical activity. These findings warrant further investigation of alvocidib combinations in newly diagnosed AML. This study was registered at clinicaltrials.gov identifier NCT03298984. PMID: 32998965 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Phase I trial of Debio 1143, an antagonist of inhibitor of apoptosis proteins, combined with cisplatin-chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head & neck.
CONCLUSIONS: The RP2D of Debio 1143 is 200 mg/day for 14 days, q3w when combined with concomitant high-dose cisplatin chemoradiotherapy in LA-SCCHN. Debio 1143 addition to chemoradiotherapy was safe and manageable. Preliminary efficacy is encouraging and supports further development. PMID: 32994295 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma.
CONCLUSIONS: Our study highlights importance of defects of DNA repair machinery in NPC pathogenesis and their prognostic values for clinical implications. These signatures will be useful for patient stratification to evaluate conventional and new treatment for precision medicine in NPC. PMID: 32988965 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer.
CONCLUSIONS: Enzalutamide with exemestane was well tolerated. While PFS was not improved by the addition of enzalutamide to exemestane in an unselected population, ET-native patients with high AR mRNA, particularly in combination with low ESR1 mRNA levels, may benefit from enzalutamide with exemestane. PMID: 32988969 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
DNA methylation profiling of premalignant lesions as a path to ovarian cancer early detection.
Authors: Ishak CA, De Carvalho DD Abstract Genome-wide DNA methylation profiles of serous tubal intraepithelial lesions (STICs) resemble methylation profiles of HGSOCs more closely than normal fallopian tube epithelium. While STICs and HGSOCs share subsets of common hypermethylated regions, DNA methylation can distinguish STICs from HGSOCs to provide proof-of-principle that DNA methylation can identify HGSOC initiation. PMID: 32988966 [PubMed - as supplied by publisher] (Source: Clinical...
Clinical Cancer Research
1w
Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation.
CONCLUSIONS: Combined tumor volume measurement and estimation of tumor regression and growth rate has potential to enhance assessment of treatment effects in clinical studies of colorectal cancer that would not be achieved with conventional, RECIST-based unidimensional measurements. PMID: 32988968 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematological cancer models without dose-limiting thrombocytopenia.
CONCLUSIONS: AZD4320 is a potent molecule with manageable thrombocytopenia risk to explore the utility of a dual Bcl-2/Bcl-xL inhibitor across a broad range of tumor types with dysregulation of Bcl-2 pro-survival proteins. PMID: 32988967 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.
CONCLUSION: outcome after post-transplant relapse among younger patients has improved significantly in recent years, likely reflecting, among other factors, the efficacy of post-transplant salvage including second allo-HCT. PMID: 32988970 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Characterizing CDK12-Mutated Prostate Cancers.
CONCLUSIONS: CDK12-altered mCRPCs have worse prognosis with these tumors surprisingly being primarily enriched for CD4+FOXP3- cells that seem to associate with worse outcome and may be immunosuppressive. PMID: 32988971 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Short Term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor Positive Breast Cancers.
CONCLUSIONS: These studies provide preclinical rationale to test CDK4/6i + RT in women with locally-advanced ER+ breast cancer at high risk for locoregional recurrence. PMID: 32967938 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
AACR Cancer Progress Report 2020: Turning Science into Lifesaving Care.
Authors: Sengupta R, Honey K PMID: 32967942 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: results from the randomized ARTE trial.
CONCLUSION: Large pre-treatment contrast-enhancing tumor mass and higher ADC identify patients who may experience a survival benefit from bevacizumab plus radiotherapy. Persistent 18FET-PET signal of no longer contrast-enhancing tumor after concomitant bevacizumab plus radiotherapy suggests pseudoresponse and predicts poor outcome. TRIAL REGISTRATION: NCT01443676. PMID: 32967939 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Autoantibody landscape in patients with advanced prostate cancer.
CONCLUSIONS: We present the first large-scale profiling of autoantibodies in advanced prostate cancer, utilizing a new antibody profiling approach to reveal novel cancer-specific antigens and epitopes. Our study recovers antigens of known importance and identifies novel tumor-specific epitopes of translational interest. PMID: 32967941 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
FDA Approval Summary: Entrectinib for the treatment of NTRK-gene fusion solid tumors.
Authors: Marcus L, Donoghue M, Aungst S, Myers CE, Helms WS, Shen G, Zhao H, Stephens O, Keegan P, Pazdur R Abstract The Food and Drug Administration (FDA) approved entrectinib on August 15, 2019, for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and...
Clinical Cancer Research
1w
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Authors: Chang E, Weinstock C, Zhang L, Charlab R, Dorff SE, Gong Y, Hsu V, Li F, Ricks TK, Song P, Tang S, Waldron PE, Yu J, Zahalka E, Goldberg KB, Pazdur R, Theoret MR, Ibrahim A, Beaver JA Abstract On December 18, 2019, the Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (PADCEV; Astellas and Seattle Genetics) for treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor,...
Clinical Cancer Research
1w
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer.
CONCLUSION: PAM50MET is prognostic in HR+/HER2-negative MBC, and further evaluation might help identify candidates for ET only or novel therapies. PMID: 32962980 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
A Self-Assembling and DisAssembling (SADA) bispecific antibody (BsAb) platform for curative 2-step pre-targeted radioimmunotherapy.
CONCLUSIONS: The SADA-BsAb platform safely delivered large doses of radioisotopes to tumors and demonstrated no toxicities to the bone marrow, kidneys or liver. Due to its modularity, SADA-BsAbs can be easily adapted to most tumor antigens, tumor types, or drug delivery approaches to improve TI and maximize the delivered dose. PMID: 32958698 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia.
CONCLUSION: Lenalidomide is efficacious with manageable toxicities as an early intervention strategy in patients with high-risk CLL, but did not enhance humoral response to PCV13 vaccine. This trial was registered with ClinicalTrials.gov Identifier: NCT01351896. PMID: 32958702 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance).
CONCLUSIONS: This is the first large GWAS ever conducted in mCRC patients treated with first-line standard treatment in a randomized phase III trial. A common SNP in AXIN1 confers worse OS and the effect is replicated in TCGA. Further studies in CRC experimental models are required. PMID: 32958699 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Response to anti-PD-1 in microsatellite stable colorectal cancer: a STAT need.
Authors: Nusrat M Abstract Most colorectal cancers are microsatellite stable with no response to anti-PD-1 therapy, necessitating the development of new immunomodulatory treatment strategies. Co-inhibition of anti-PD-1 and STAT3 can elicit an effective anti-tumor response in a small subset of microsatellite stable colorectal cancer patients, and biomarkers predictive of response are under investigation. PMID: 32958701 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Delving into Early Onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?
CONCLUSIONS: Our comprehensive analysis of sequencing data generated from a large cohort of PDAC patient samples highlights a distinctive pattern of bi-allelic CDKN2A mutation in EOPC tumors. Increased expression of FOXC2 in EOPC, with the correlation between FOXC2 and EMT pathways, represent novel molecular characteristics of EOPC. PMID: 32958704 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Protein glycosylation: 'new-yet-old' target for immunotherapy.
Authors: Bhat J, Kabelitz D Abstract The use of checkpoint monotherapy in treating cancer has limited success. Post-translational modifications (PTM) of proteins such as glycosylation might have clinical implications due to distinct modifications found in diseases and its regulatory role in the immunometabolic gene expression. Such novel mechanistic targets hold great promise for combined immunotherapy. PMID: 32958703 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Siglec-15 as an emerging target for next-generation cancer immunotherapy.
Authors: Sun J, Lu Q, Sanmanmed MF, Wang J Abstract Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to treat cancer. The explanation underlying the success of these agents may be the selective expression of PD-L1 with dominant immune-suppressive activities in the tumor microenvironment (TME), supporting a more favorable tumor response-to-toxicity ratio. However, despite the big success of these drugs, most cancer patients show primary or acquired resistance,...
Clinical Cancer Research
1w
Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I related Plexiform Neurofibromas.
CONCLUSIONS: Pexidartinib in pediatric pts was well tolerated at all DL tested, achieved target inhibition and resulted in a weight based RPD2 dose. PMID: 32943455 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Amphiregulin expression is a predictive biomarker for EGFR inhibition in metastatic colorectal cancer: combined analysis of three randomized trials.
CONCLUSIONS: High AREG mRNA expression is a favorable prognostic biomarker for mCRC which interacted significantly with efficacy of anti-EGFR treatment. PMID: 32943459 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.
CONCLUSIONS: Concurrent administration of enzalutamide and crizotinib resulted in a clinically significant 74% decrease in systemic crizotinib exposure. Further investigation of this combination in CRPC is not planned. Our results highlight the importance of evaluating pharmacokinetic interactions when evaluating novel combination strategies in CRPC. PMID: 32943461 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
STAT3 antisense oligonucleotide remodels the suppressive tumor microenvironment to enhance immune activation in combination with anti-PD-L1.
CONCLUSIONS: STAT3 ASO treatment reverses a suppressive TME and promotes pro-inflammatory gene expression changes in patients' tumors and mouse models. Preclinical data provide evidence that ASO-mediated inhibition of STAT3 in the immune compartment is sufficient to remodel the TME and enhance the activity of checkpoint blockade without direct STAT3 inhibition in tumor cells. Collectively, these data provide rationale for testing this combination in the clinic. PMID: 32943458 [PubMed - as supplied...
Clinical Cancer Research
1w
Phase 1B Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
CONCLUSION: Treatment with PPE and erlotinib combination was well tolerated in patients with APLs of the head and neck, and showed a high rate of pathologic response with excellent CFS. This combination deserves further investigation for the chemoprevention and/or prevention of second primary tumors in early stage head and neck cancer. PMID: 32943457 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Intratumoral Immunotherapy: from Trial Design to Clinical Practice.
Authors: Champiat S, Tselikas L, Farhane S, Raoult T, Texier M, Lanoy E, Massard C, Robert C, Ammari S, De Baere T, Marabelle A Abstract Systemic immunotherapies such as immune checkpoint blockade targeted at PD(L)1 and CTLA4 have demonstrated their ability to provide durable tumor responses and long term overall survival benefits for some patients in several solid tumor types. However, a majority of patients remain resistant to these treatments and a significant proportion of them develop...
Clinical Cancer Research
1w
Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer.
CONCLUSIONS: ILC metastases harbor genomic alterations that may potentially explain endocrine resistance in a large proportion of patients, and present genomic differences as compared to IDC metastases. PMID: 32943456 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial.
CONCLUSION: Palbociclib in combination with trastuzumab is safe and exhibits promising survival outcomes in trastuzumab pre-treated ER-positive/HER2-positive advanced breast cancer with a PAM50 luminal A or B subtype. The enrollment was stopped prematurely and a new randomized cohort was opened in this population. PMID: 32938620 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
Authors: Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, Song X, Wang W, Dong L, Song H, Wu H, Feng H, Yao S, Qin S, Zhang X, Guo J PMID: 32934029 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Serum IL-6 as a prognostic biomarker and IL-6R as a therapeutic target in biliary tract cancers.
CONCLUSIONS: Serum IL-6 and YKL-40 are potential new prognostic biomarkers in BTC. IL-6 provides independent prognostic information and may be superior to CA19-9 in certain contexts. Moreover, anti-IL-6R should be considered as a new treatment option to sustain gemcitabine response in BTC patients. PMID: 32933994 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
CONCLUSIONS: This study indicates PPI use is a negative prognostic marker in advanced urothelial carcinoma treated with ICI therapy, but not chemotherapy. Furthermore, the analysis suggests PPIs influence the magnitude of ICI efficacy, and this warrants further investigation. PMID: 32933995 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Authors: Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC PMID: 32934031 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
TSPO-targeted PET and Optical Probes for the Detection and Localization of Pre-Malignant and Malignant Pancreatic Lesions.
CONCLUSIONS: We anticipate that combined TSPO PET/IGS represents a translational approach for precision pancreatic cancer care through discrimination of high-risk indeterminate lesions and actionable surgery. PMID: 32933996 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Selected Articles from This Issue.
Authors: PMID: 32934028 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Chloroquine sensitizes GNAQ/11-mutated melanoma to MEK1/2 inhibition.
CONCLUSIONS: These results suggest that YAP, MEK1/2, and lysosome function are necessary and critical targets for the therapy of GNAQ/11-driven melanoma, and identify trametinib plus hydroxychloroquine as a potential treatment strategy for metastatic uveal melanoma. PMID: 32933997 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Correction: Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion.
Authors: Ryu D, Kim SJ, Hong Y, Jo A, Kim N, Kim HJ, Lee HO, Kim K, Park WY PMID: 32934030 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer.
CONCLUSIONS: Collectively, these results demonstrate the all-in-one potential of 64Cu-RaftRGD for imaging-guided radiotherapy of OCPM by targeting both tumoral neovessels and cancerous cells. Based on the ITD finding, we propose that pairing αVβ3- and hypoxia-targeted radiotherapies could improve therapeutic efficacy by overcoming the heterogeneity of ITD encountered with single-agent treatments. PMID: 32933998 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Editor's Note: The Pivotal Role of Integrin β1 in Metastasis of Head and Neck Squamous Cell Carcinoma.
Authors: Wang D, Müller S, Ruhul Amin ARM, Huang D, Su L, Hu Z, Rahman MA, Nannapaneni S, Koenig L, Chen Z, Tighiouart M, Shin DM, Chen ZG PMID: 32934033 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w
Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Authors: Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, Donovan D, Cobham MV, Fitzpatrick V, Schneider S, Wiener A, Guillaume-Abraham J, Aljom E, Zelkowitz R, Warren JD, Lane ME, Fischbach C, Mittal V, Vahdat L PMID: 32934032 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
1w

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου